5th Inflammasome Therapeutics Summit returns to Boston!
The 5th Inflammasome Therapeutics Summit returns to Boston to unite industry pioneers at a critical time as clinical readouts are expected, and a wave of new collaborations hit the headlines.
As we focus on targeting beyond NLRP3 for treating inflammation, this is your chance for you to join forces with like-minded individuals who prioritize inflammasome therapeutics.
Together, we can address important aspects including discovery science and mechanisms, overcoming biomarker challenges such as measuring target engagement, disease selection, and making progress in developing preclinical models.
This is the largest gathering of inflammasome biopharma experts and pioneers set to advance inflammasome inhibitors and activators from the pipeline to in-human efficacy.
Gathering industry super giants, including NodThera, Zydus Therapeutics, Novartis, Roche, Ventus, AC Immune, and more, this is your chance to join forces with 100+ inflammasome pioneers for interactive discussions.